Novo Nordisks trials, called evoke and evoke+, involved 3,808 people aged 55 to 85 who had early-stage Alzheimers, classified as having mild cognitive impairment as a result of the disease
Here is a rundown of this weeks business news across the valley
Ismail AM, Hamed AH, Saso S, Thabet HH
Standard preprocessing of the SomaScan array data was performed in accordance with guidance from SomaLogic
GHK-Cu attracts immune cells (macrophages, mast cells) and endothelial cells to injury sites, stimulates angiogenesis (new blood vessel formation), and promotes nerve outgrowth
That openness is the pitch, and it undercuts Peak Wellnesss month-to-month rate